Autopsy report · NCT04368897

In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity

“Not able to recruit subjects”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Sponsor

Applied Biology, Inc.

Sponsor type

Industry

Conditions

SARS-CoV 2; COVID; COVID-19; Androgenetic Alopecia; Androgen Receptor Abnormal; Androgen Deficiency

Interventions

CAG length <22; CAG length >=22

Participants

0

Sites

1

Countries

Spain

Trials that died the same way

• Repaglinide for Adolescents With Cystic Fibrosis-Related Diabetes
  “Unable to recruit any subjects” (97% match in meaning)
• Recombinant Human Prolactin for Lactation Induction
  “Not able to recruit any subjects.” (94% match in meaning)
• FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan
  “inability to recruit subjects” (87% match in meaning)
• Prospective Evaluation of Symptom Resolution in Acid Versus Non-acid Reflux Disease Following Anti-reflux Surgery
  “Unable to recruit a sufficient number of subjects.” (86% match in meaning)
• Effect of Externally Implantable Tissue Expansion Device on Scar Length
  “Inability to recruit eligible subjects” (86% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.